Results 131 to 140 of about 47,659 (253)

Compartmentalisation in cAMP signalling: A phase separation perspective

British Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Neuroprotective Effects of Phosphodiesterase Inhibitors on Sestrin-2 (SESN2) Expression and Autophagy in Alzheimer's Disease Model. [PDF]

Cureus
Faikoglu G, Saygisever-Faikoglu K, Ozbasak H, Ugur SA, Uskur T, Akkan AG, Kelicen-Ugur P, Ozyazgan S.   +7 more
europepmc   +1 more source

Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist. [PDF]

ACS Chem Neurosci, 2020
Ribaudo G, Ongaro A, Zagotto G, Memo M, Gianoncelli A.   +4 more
europepmc   +1 more source

Potential Cancer- and Alzheimer's Disease-Targeting Phosphodiesterase Inhibitors from Uvaria alba: Insights from In Vitro and Consensus Virtual Screening. [PDF]

ACS Omega, 2021
Quimque MT, Notarte KI, Letada A, Fernandez RA, Pilapil DY, Pueblos KR, Agbay JC, Dahse HM, Wenzel-Storjohann A, Tasdemir D, Khan A, Wei DQ, Gose Macabeo AP.   +12 more
europepmc   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Back to phosphodiesterase inhibitors for liver disease: Are we ready for clinical trials? [PDF]

Hepatology
Gobejishvili L, McClain CJ.
europepmc   +1 more source

Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale. [PDF]

J Alzheimers Dis Rep, 2020
Sanders O, Rajagopal L.
europepmc   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Efficacy of Novel Pyrazolone Phosphodiesterase Inhibitors in Experimental Mouse Models of Trypanosoma cruzi. [PDF]

Antimicrob Agents Chemother, 2020
de Araújo JS, França da Silva C, Batista DDGJ, Nefertiti A, Fiuza LFA, Fonseca-Berzal CR, Bernardino da Silva P, Batista MM, Sijm M, Kalejaiye TD, de Koning HP, Maes L, Sterk GJ, Leurs R, Soeiro MNC.   +14 more
europepmc   +1 more source